SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · PRV acquisition $205M

BioNTech SE · 6-K filed Nov 10, 2026 at 07:01 ET

At the news

NEUTRALIMPACT 4/10

6-K filed Nov 10, 2026 at 07:01 ET

BioNTech announced it will acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash. The PRV will be used to support a future regulatory filing for a late-stage oncology asset, potentially accelerating approval timelines.

  • BioNTech agreed to acquire an FDA Priority Review Voucher from Scholar Rock for $205 million in cash.
  • The PRV reduces the FDA review timeline for a single application and could lead to expedited approval.
  • BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline.
  • The transaction is subject to customary closing conditions, including HSR antitrust clearance.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access